CEAxCD28 Bispecific Antibody for Solid Tumor Immune Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunotherapies using T cell bispecific antibodies or CAR T cells have shown limited effectiveness in treating solid cancers, leaving many patients without valid therapeutic options.

Innovation Solution

The use of CEAxCD28 bispecific antibodies in combination with a PD-1 blocking antibody to stimulate T cell activation and enhance anti-tumor activity in solid cancers.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If T cell bisspecific antibodies or CAR T cells are used to stimulate immune cells to attack cancer cells, then anti-tumor response is improved in hematological malignancies, but effectiveness deteriorates in solid cancers

Engineering Contradiction:

Improveanti-tumor response effectivenessVSAvoidapplicability to different cancer types

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent introduces a costimulatory domain (CD28 or 4-1BB) specific to the tumor microenvironment, creating a localized enhancement of T cell activation precisely where needed. This allows the bispecific antibody to provide targeted costimulatory signals at the tumor site without requiring systemic activation, thereby improving effectiveness in solid cancers while maintaining specificity.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent combines two functional domains into a single bispecific antibody molecule: the tumor-targeting domain and the costimulatory domain. This composite structure integrates the tumor-specific binding capability with enhanced T cell activation signals, creating a multifunctional therapeutic agent that overcomes the limitations of monospecific antibodies in solid cancer treatment.

Inventive Principle:

Principle #40Composite materials

2Reliability

If costimulatory signals are activated to enhance T cell response, then anti-tumor activity is improved, but immune system complexity increases

Engineering Contradiction:

ImproveT cell activation effectivenessVSAvoidimmune system modulation complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges the tumor-targeting function and costimulatory activation function into a single bispecific antibody molecule. By combining these two functions in one agent, the patent simplifies the therapeutic approach while achieving enhanced T cell activation through costimulatory signals, avoiding the need for multiple separate interventions.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The bispecific antibody acts as an intermediary molecule that bridges the tumor cell (via tumor-associated antigen binding) and the T cell (via CD3 and costimulatory receptor binding). This intermediary approach facilitates controlled T cell activation through costimulatory signals without requiring direct manipulation of the complex immune system pathways.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250075000A1Combination therapy with a CEA x CD28 bispecific antibody and blocking Anti-PD-1 antibodies for enhanced in vivo Anti-tumor activity

Publication Date: 2025.03.06 NOVIMMUNE SA

AI summary

The invention provides a CEAxCD28 bispecific antibody for the CEA-targeted costimulation of tumor infiltrating T cells in combination with antibodies which block the PD-L1/PD-1 pathway, for use in the combination treatment for stimulating an immune response against cancer or tumor.